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Abstract
Background—In the United States, the seasonality of respiratory syncytial virus (RSV) has 
traditionally been defined on the basis of weeks during which antigen-based tests detect RSV in 
>10% of specimens (hereafter, the “10% threshold”). Because molecular testing has become more 
widely used, we explored the extent of polymerase chain reaction (PCR)–based RSV testing and 
its impact on determining the seasonality of RSV.
Methods—We assessed antigen- and PCR-based RSV reports submitted to the National 
Respiratory and Enteric Virus Surveillance System during July 2005–June 2015. To characterize 
RSV seasons by using PCR-based reports, we assessed the traditional 10% threshold; 
subsequently, we developed 3 methods based on either PCR-based detections or the percentage of 
positive test results.
Results—The annual number of PCR-based reports increased 200-fold during 2005–2015, while 
the annual number of antigen-based reports declined. The weekly percentage of specimens 
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positive for RSV by PCR was less than that for antigen-detection tests; accordingly, the 10% 
threshold excluded detections by PCR and so was imprecise for characterizing RSV seasons. 
Among our PCR-specific approaches, the most sensitive and consistent method captured 96%–
98% of annual detections within a season, compared with 82%–94% captured using the traditional 
method.
Conclusions—PCR-based reports are increasingly relevant for RSV surveillance and 
determining the seasonality of RSV. These PCR-specific methods provide a more comprehensive 
understanding of RSV trends, particularly in settings where testing and reporting are most active. 
Diagnostic practices will vary by locality and should be understood before choosing which method 
to apply.
Keywords
RSV surveillance; RSV season; season threshold; antigen diagnostic tests; molecular diagnostic 
tests
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in 
young children worldwide [1]. In the United States, RSV is responsible for >50 000 
hospitalizations and 2 million outpatient visits annually among children aged <5 years [2]. 
Among US adults aged ≥65 years, RSV is associated with an estimated 177 000 annual 
hospitalizations and 14 000 deaths [3]. There is currently no approved RSV vaccine, but 
immunoprophylaxis is available for high-risk infants [4].
The Centers for Disease Control and Prevention (CDC) has traditionally described national 
RSV circulation by using antigen-based RSV tests, with frequencies of positive results 
reported to the National Respiratory and Enteric Virus Surveillance System (NREVSS) [5]. 
Similar to the definition used previously to describe the influenza season [6], the annual 
season of RSV was defined for epidemiologic purposes on the basis of weeks during which 
antigen-based tests detect RSV in >10% of specimens (hereafter, the “10% threshold”) [7, 
8]. By use of this method, the national RSV season is typically from fall through spring, but 
season onset varies between US regions [8, 9] and between smaller locales [10, 11]. During 
the past decade, many clinical laboratories have adopted molecular diagnostic assays to 
detect RSV (and other respiratory viruses) [12] because of improved sensitivity (and often 
specificity) as compared to antigen-detection tests or virus isolation [13]; RSV diagnostic 
assays continue to evolve [14]. Given these changes, we assessed each RSV test type for 
which data were reported to NREVSS and evaluated RSV circulation on the basis of 
molecular- and antigen-based diagnostic methods.
Methods
Data Collection
NREVSS is a national passive surveillance network that collects weekly aggregate test 
results for RSV and other viruses from clinical, public health, and reference laboratories [5]. 
Reports are categorized on the basis of the following 3 diagnostic methods: virus isolation 
by culture, antigen-based methods, or polymerase chain reaction (PCR)–based methods 
(which includes all reported molecular-based diagnostic platforms). NREVSS surveillance 
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year begins on the first week with at least 4 days in July (typically epidemiologic week 27) 
and ends the following year on the last week with at least 4 days in June (typically 
epidemiologic week 26). To limit our analysis to laboratories that consistently reported data, 
we included those that reported results for an average of ≥10 RSV tests per week annually 
for at least 30 weeks of NREVSS year [8], during July 2005–June 2015; we applied these 
criteria to data from the 3 diagnostic methods separately. For each week in a given 
surveillance year, we also assessed the number of consistent reporters that had submitted 
RSV data to NREVSS; this was done to ensure that a sufficient proportion of annual 
consistent reporters were contributing throughout the year.
To assess recent laboratory-specific practices for detection of RSV and other respiratory 
viruses, we interviewed laboratory staff by telephone from a convenience sample of 
NREVSS reporters across the country. We used a standard questionnaire that included 
questions about diagnostic testing methods, testing practices, and laboratory changes during 
the previous 5 surveillance years (2009–2014).
Data Analysis
To assess reporting trends across the United States, we compared reports from NREVSS 
laboratories that consistently reported data on each diagnostic method, by year and by 
geographical distribution. To explore the characteristics of RSV seasons with PCR-based 
reports, we assessed the weekly number of RSV tests performed, the number of tests 
detecting RSV, and the corresponding percentage of tests positive for RSV during July 
2009–June 2015; prior to July 2009, PCR-based reports were considered too few for reliable 
analysis of RSV seasons. To characterize the RSV season with PCR data, we first assessed 
the traditional 10% threshold [7, 8]. We subsequently explored a variety of different 
approaches, which varied in complexity, to identify notable and sustained increases in either 
RSV detections or the percentage of tests detecting RSV. We assessed various data-
smoothing techniques, including the use of moving averages or polynomial regression, and 
we explored approaches that could be applied to data retrospectively or in near real time. 
Finally, we developed 3 new methods for characterizing season with PCR data, based on (1) 
the increase (or slope) in the number of RSV detections, by week; (2) the number of RSV 
detections relative to the preseason baseline, by week; and (3) the percentage of tests 
detecting RSV, by week.
With each approach, we determined season characteristics nationally and by census region, 
including season onset (or start), duration, peak, offset (or end), and percentage of annual 
detections that occur within the season (ie, from onset to offset). We compared these 
measures to those derived from the traditional method, which uses data from antigen-
detection tests, and we assessed relative strengths and weaknesses of each approach. The 
virus isolation data were not used to assess season characteristics.
Descriptive and quantitative analyses were conducted using Microsoft Access 2010, 
Microsoft Excel 2010, SAS 9.3, and R statistical computing software (version 3.3.1).
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Results
During July 2005–June 2015, the number of laboratories reporting to NREVSS varied, 
peaking in 2008–2009 at 724 (Figure 1A); not all laboratories met our definition for 
consistent reporting. Across the 10 surveillance years, the number of laboratories 
consistently reporting PCR-based RSV results steadily increased from 2 to 82, while 
laboratories consistently reporting antigen or viral culture results declined (Figure 1A). 
During surveillance year 2014–2015 (July 2014 to June 2015), more PCR-based RSV tests 
than antigen–based RSV tests were performed and submitted to NREVSS from consistent 
reporters (Figure 1B); the number of PCR-based reports of RSV detection was also higher 
than for antigen-based reports (Figure 1C). Additionally, laboratories that consistently 
reported PCR results during 2014–2015 were distributed across more states (n = 37) than 
those consistently reporting results of either antigen-detection tests (n = 32) or virus 
isolation (n = 21; Supplementary Figure 1). For each week of a given surveillance year 
(including the summer months), more than half of the laboratories consistently reporting 
PCR findings contributed to NREVSS.
To further assess recent testing practices for RSV and respiratory pathogens, we interviewed 
a convenience sample of laboratories reporting findings to NREVSS reported during 
January–August 2014. Survey participants included 108 clinical laboratories from 48 states; 
all tested for RSV, and 96% (104) tested for RSV throughout the year. Testing practices 
varied by site; only 31% of sites (33 of 108) reported use of a standard protocol in selecting 
testing methods for respiratory samples, whereas 45% (49 of 108) followed a physician 
order, and 20% (22 of 108) reported temporarily changing practices outside the RSV season. 
Corroborating our NREVSS findings, 87% of interview respondents (94 of 108) had 
changed their respiratory sample testing practices in the previous 5 years; 62% (59 of 94) 
reported increased use of molecular testing, 14% (13 of 94) reported discontinued or 
decreased use of virus isolation methods, and 9% (8 of 94) reported discontinued or 
decreased use of antigen-detection tests.
Given this increase in PCR-based reporting, we analyzed attributes affecting the definition of 
an RSV season. We assessed weekly RSV tests, detections, and percentages of tests positive 
for RSV among PCR- and antigen-based reports during July 2009–June 2015 (Figure 2 
[national] and Supplementary Figure 2 [regional]). The weekly percentage of tests positive 
for RSV was notably lower for PCR-based reports than for antigen-based reports (Figure 
2C), and so the PCR and antigen data were not combined for further analyses. When applied 
to the PCR-based data, the 10% threshold yielded season onsets between weeks 47–52 and 
offsets between weeks 10–12 of the following calendar year (Figure 2C). This equated to 
season durations of 13–18 weeks, which captured only 72%–82% of annual detections by 
PCR within season. By comparison, the antigen-based data yielded season durations of 19–
31 weeks, and captured 82%– 94% of annual detections by antigen-detection tests within 
seasons. Because the 10% threshold excluded applicable detections by PCR, it was deemed 
inappropriate for use with PCR-based reports. New approaches for characterizing RSV 
seasons by means of PCR-based reports were therefore explored.
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Further investigation of reported data on testing and detection revealed that variations in 
PCR testing might inconsistently influence the percentage of tests positive for RSV. During 
October–November 2009, the number of RSV PCR tests peaked dramatically, more so than 
antigen-detection tests (Figure 3). This anomaly was likely reflective of multipathogen PCR 
use during the influenza A(H1N1) pandemic [15, 16]. At the same time, RSV detections 
were starting to rise, but because the increase in detections was marginal compared to the 
increase in tests, the increase in percentage of tests positive for RSV was delayed. Because 
tests intended for detection of other respiratory pathogens might influence the denominator 
for the percentage of tests positive for RSV across a surveillance year, we assessed the 
usefulness of RSV detections alone for defining seasons. National (Figure 2B) and regional 
(Supplementary Figure 2B) detections by PCR increased across the 6 years and exhibited 
consistent trends each year.
Based on RSV detections, we developed the retrospective slope 10 (RS10) method to reflect 
weekly changes in detections as precisely and consistently as possible (Table 1). We used a 
centered 5-week moving average of weekly RSV detections to smooth weekly variation. We 
then normalized these data (ie, put them on an equal scale) to a season peak of 1000 
detections to allow comparisons between seasons and regions (Figure 4A [national] and 
Supplementary Figure 3 [regional]). We defined the season onset as the second of 2 
consecutive weeks when the slope (ie, the simple increase in the normalized 5-week moving 
average between subsequent weeks) exceeded 10 normalized detections per week, provided 
that the slope exceeded 10 from that week forward. During July 2009–June 2015, the RS10 
method yielded national season onsets between weeks 38 and 45, which corresponded to a 
sustained rise in normalized detections (Figure 4A).
To provide a near real-time approximation to the retrospective national and regional onset 
estimates yielded by the RS10 method, we developed the 10-fold baseline (10FB) method, 
which compares RSV detections in a given week to those at the preseason baseline (Table 
1). To smooth weekly variation, we chose a 4-week moving average of RSV detections in 
the 2 previous weeks, the current week, and 1 week ahead; this 4-week moving average was 
chosen over a 5-week moving average to reduce (from 2 weeks to 1 week) the time lag for 
identifying a real-time season onset. The 4-week moving average at each week was then 
presented as a fold increase from the preseason baseline (Figure 4B [national] and 
Supplementary Figure 4 [regional]). For the national and regional analyses, we defined the 
preseason baseline as the 4-week moving average at week 29 because (1) it centered weeks 
26–33, which typically had the lowest detections in the surveillance year, both nationally 
and regionally (Supplementary Figure 5); (2) a consistent number of laboratories reported to 
NREVSS in week 29 (Supplementary Table 1); and (3) a consistent number of detections 
were reported in week 29 (Supplementary Table 1). We defined season onset as the first of 2 
consecutive weeks when the 4-week moving average of detections was >10 times the 
detections at week 29; the 10-fold measure was both simple and applicable across census 
regions. Based on the 10FB method, national season onsets during July 2009–June 2015 
were between weeks 42 and 45.
Finally, we developed a method that defined season onset as the first of 2 consecutive weeks 
when the weekly percentage of tests positive for RSV was >3% (hereafter, the “3% 
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threshold”; Figure 4C [national] and Supplementary Figure 6 [regional]). We chose this 
threshold because the national and regional percentage of tests positive for RSV throughout 
the summer months was typically <3%; once the 3% threshold was exceeded, the percentage 
of tests yielding RSV continued to increase rapidly. This third method provided a simple 
approach that accounted for the number of tests performed. Based on the 3% threshold, 
national season onsets during July 2009–June 2015 were between weeks 42 and 46.
We compared methods by evaluating how closely the onset weeks reflected changes in raw 
(unadjusted) RSV detections (Figure 5A). For each surveillance year, the national onset 
determined by the RS10 method identified a consistent part of the curve that corresponded 
with a notable and sustained rise in raw (unadjusted) weekly RSV detections. The RS10 
method also appeared to reflect changes in national RSV detections more sensitively than 
any other method. For each method, we also evaluated the consistency across surveillance 
years of season characteristics, such as season duration and the proportion of annual 
detections captured (Table 2). The RS10 method most consistently captured a similar 
percentage of the annual detections within seasons across the 6 surveillance years; this was 
the case both nationally (Table 2) and within most census regions (Supplementary Tables 2–
5). The 10FB and 3% threshold methods provided reasonable real-time approximations to 
the retrospective estimates yielded by the RS10 method.
Overall, the 3 PCR methods typically defined the national season onset earlier in the year 
than did the 10% threshold method (ie, the traditional antigen-detection method), and the 
RSV season was typically longer; except in 2012–2013, when the season onset as 
determined by the 10% threshold method was considerably earlier (Figure 5 and Table 2). 
Based on the RS10 method, national RSV seasons started a median of 3 weeks earlier and 
ended 5.5 weeks later than when traditionally defined. Nationally, this new approach 
captured 96%–98% of annual RSV detections within season, compared with 82%–94% 
captured using the 10% threshold method.
Discussion
RSV diagnostic testing practices are changing, driven by the increasing use of molecular 
diagnostic assays. We document the increasing use of PCR diagnostic assays for RSV 
detection across the United States over the past decade, accompanied by a simultaneous 
decrease in use of antigen-detection assays and virus isolation by culture. The impact of 
such changes on RSV surveillance and determining the seasonality of RSV, however, had 
not been previously addressed. Our study uses recent national RSV surveillance data to 
compare methods to more precisely determine season onset and duration and to better define 
the role of PCR diagnostic tests in these determinations.
While increased use of PCR is reported across the United States, many laboratories still 
report antigen-detection methods for RSV; this is likely because rapid antigen-detection tests 
are inexpensive, fast, and easy to use [12, 17, 18]. To determine RSV season onset and 
duration, however, PCR-based reports must be evaluated differently than antigen-based 
reports. Historically, the CDC has determined RSV seasonality by using the frequency of 
antigen-based tests positive for RSV[8–11, 19]. Because the overall percentage of tests 
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positive for RSV was consistently lower with PCR-based reports than with antigen-based 
reports, the 2 test types could not be meaningfully combined, and the traditional 10% 
threshold was inappropriate for PCR-based reports. The lower PCR baselines may reflect 
increased clinical use of multipathogen PCR panels; by contrast, antigen-based assays more 
often reflect tests targeting RSV only. Given these findings, we developed new approaches 
to interpret the PCR data, based on reports submitted nationally and by census region. As 
RSV diagnostic methods continue to evolve, we anticipate refining our seasonality 
approaches as needed to facilitate a more complete understanding of RSV circulation.
For jurisdictions receiving PCR test results from consistent reporters throughout the year 
(including the summer), season onset and duration can be determined retrospectively by 
using a normalized 5-week moving average of RSV detections. With this method (RS10), 
we were able to consistently capture 96%– 98% of annual detections nationally within a 
season (between onset and offset). Because of this consistency and because this approach 
best identified sustained increases in RSV detections to define season onset, in the future the 
CDC will use this method to characterize an RSV season retrospectively. When a real-time 
estimate is needed, however, RSV season could be determined using a threshold that 
represents an increase relative to a predefined preseason baseline. Our 10FB method for 
national and regional data used a 10-fold increase in RSV detections relative to the 4-week 
moving average at week 29 and captured 95%–98% of national annual detections within 
season. With data from smaller jurisdictions, a locally tailored baseline should be 
considered. Consistent testing is required for both RS10 and 10FB because the testing 
denominator is not incorporated into the season determination and because the weekly data 
are presented relative to other weeks. These methods may therefore not be generalizable to 
all state or local jurisdictions. Local testing practices and surveillance should be understood 
before using these methods.
Our third PCR-specific approach—the 3% threshold—incorporates the RSV tests performed 
to determine the weekly percentage of tests positive for RSV, as was used traditionally for 
antigen-based reports; no further data functions are required. This simple approach might 
allow for a reasonable estimation of RSV season in public health jurisdictions where RSV 
testing is not performed or reported throughout the year. While the 3% thresholds reflected 
national and regional data well, the threshold for interpreting data from smaller jurisdictions 
may vary by location. An important limitation in this approach, however, is the inclusion of 
tests not intended for RSV; multipathogen PCR panels used when other respiratory viruses 
are circulating could, using this approach, influence identification of the RSV season 
inconsistently. Local testing practices should therefore be assessed. As with the other 
methods, contribution from consistent reporters strengthens season estimates.
Regardless of the specific approach chosen, PCR methods yielded earlier season onsets and 
longer seasons than traditionally described. Because consistent PCR-based reporting has 
become more representative nationally than antigen-based reporting, these longer season 
determinations likely represent RSV circulation more precisely. Additionally, RSV PCR 
tests are more sensitive (and sometimes more specific) than rapid antigen-detection tests 
among children and especially adults [13], meaning that PCR can be used across all ages; 
antigen-detection tests are typically limited to infants and children. This is especially 
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relevant in light of candidate vaccines targeting older adults [20–23] and pregnant women 
[20–22, 24–26], because RSV circulation among adults is not well described and likely 
underestimated [27].
Over 60 new candidate RSV vaccines and monoclonal antibodies are currently in various 
stages of clinical trials [20, 25, 28–30]. Future effectiveness studies will benefit from a more 
precise estimate of prevaccine RSV circulation, made possible by PCR testing. Additionally, 
the timing of future RSV vaccine delivery in certain populations might also be influenced by 
seasonality, as with the seasonal influenza vaccine [31]. PCR-based estimates of the RSV 
season could also contribute to decision making regarding immunoprophylaxis use, although 
such considerations would also need to account for RSV disease, RSV hospitalizations, and 
cost-effectiveness.
Our study had several limitations. We analyzed reports to NREVSS, which is a passive and 
voluntary surveillance system in which the number of participating laboratories can vary 
between seasons, patient demographic characteristics and specific specimen information are 
not collected, duplication is possible if both antigen-based and PCR tests are performed on 
the same specimen or if multiple specimens are reported from a single patient, and severity 
of illness, such as the need for hospitalization, is not known. RSV detections, especially 
those from PCR-based virus panels, could occasionally represent RSV codetections and 
might not reflect RSV illness. Our season analyses reflected NREVSS data compiled 
nationally and by census region; with data from smaller jurisdictions, our new methods may 
be less precise than locally tailored determinations. Finally, the onset definitions for our new 
methods were arbitrary to some degree; for example, with 10FB, an 8–13-fold increase from 
baseline would have yielded similar onsets (±1 week) to those for a 10-fold increase, but the 
10-fold increase was chosen for simplicity.
RSV PCR results are now reported more widely across the United States than results of 
either antigen-detection tests or virus isolation methods and are increasingly important for 
routine RSV surveillance. Determining RSV seasonality with PCR-based reports is critical 
for providing a more comprehensive understanding of RSV circulation for epidemiologic 
purposes.
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Figure 1. 
Reporting of respiratory syncytial virus (RSV) diagnostic data by National Respiratory and 
Enteric Virus Surveillance System (NREVSS) laboratories during July 2005–June 2015. A, 
Numbers of all reporting laboratories (bars) and those consistently reporting data for each 
diagnostic method (lines). B and C, RSV tests from consistent reporters (B) and RSV 
detections from consistent reporters (C), by surveillance year and diagnostic method. 
NREVSS laboratories that consistently reported data are defined here as those that reported 
data for an average of ≥10 RSV tests per week annually for at least 30 weeks of NREVSS-
defined year. PCR, polymerase chain reaction.
Midgley et al. Page 11
J Infect Dis. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Comparison of respiratory syncytial virus (RSV) data from polymerase chain reaction (PCR) 
and antigen-detection tests, based on weekly numbers of RSV tests (A) and detections (B) 
and the weekly percentage of tests positive for RSV (C) across 6 surveillance years during 
July 2009–June 2015, by diagnostic method. The dashed line in panel C represents the 10% 
threshold. All data are limited to National Respiratory and Enteric Virus Surveillance 
System (NREVSS) laboratories that consistently reported data, defined here as those that 
reported data for an average of ≥10 RSV tests per week annually for at least 30 weeks of 
NREVSS-defined year. Surveillance started at week 27 for all years except 2009–2010, 
during which it started at week 26. Calendar years ended at week 52 for all years except 
2014, which ended at week 53; there is therefore a gap in some of the data curves.
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Figure 3. 
Comparison of respiratory syncytial virus (RSV) tests, detections, and percentage of tests 
positive for RSV during July 2009–June 2010, by diagnostic method. RSV tests are 
represented on a different scale to either of the axes depicted; the peak numbers of RSV tests 
are instead shown on the figures. Data are limited to National Respiratory and Enteric Virus 
Surveillance System (NREVSS) laboratories that consistently reported data, defined here as 
those that reported data for an average of ≥10 RSV tests per week annually for at least 30 
weeks of NREVSS-defined year. The 2009–2010 surveillance year started at week 26 in 
2009 and ended in week 26 in 2010. The 2009 calendar year ended at week 52.
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Figure 4. 
Methods for defining respiratory syncytial virus (RSV) season, using RSV detections 
reported on the basis of polymerase chain reaction (PCR) diagnostic assays. A, Generation 
of onset week, using the retrospective slope 10 (RS10) method. The normalized centered 5-
week moving average of weekly RSV detections by PCR during July–June are shown for 
each surveil-lance year. The onset week for each season is depicted by a solid circle of the 
same color. B, Generation of onset week, using the 10-fold baseline (10FB) method. The 4-
week moving average of weekly RSV detections by PCR, relative to the 4-week moving 
average at week 29, are shown for each surveillance year during July–June. The horizontal 
line represents the 10-fold increase in detections relative to week 29. The onset week for 
each season is a solid circle of the same color. C, Generation of onset week, using the 3% 
threshold method. The weekly percentage of tests positive for RSV is shown for each 
surveillance year during July–June. The horizontal line represents the 3% threshold. The 
onset week for each season is a solid circle of the same color. All data are limited to 
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National Respiratory and Enteric Virus Surveillance System (NREVSS) laboratories that 
consistently reported data, defined here as those that reported data for an average of ≥10 
RSV tests per week annually for at least 30 weeks of NREVSS-defined year. Surveillance 
started at week 27 for all years except 2009–2010, during which it started at week 26. 
Calendar years ended at week 52 for all years except 2014, which ended at week 53; there is 
therefore a gap in some of the data curves.
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Figure 5. 
Comparison of respiratory syncytial virus (RSV) seasons, generated by 4 different methods. 
A, National estimates for season onset and offset generated by the 4 methods overlaid on the 
weekly raw (unadjusted) RSV detections. Each graph represents a different surveillance 
year, as labeled. Weekly detection of RSV by both polymerase chain reaction (PCR; black 
data curve) and antigen-detection (yellow data curve) tests are depicted. Season onset and 
offset are shown for (1) the 10% threshold method (ie, the traditional antigen-based method; 
vertical yellow lines), (2) the 3% threshold method (vertical green lines), (3) the 10-fold 
baseline (10FB) method (vertical blue lines), and (4) the retrospective slope 10 (RS10) 
method (vertical black lines). B, Comparison of season characteristics for the 4 methods 
during July 2009–June 2015. Depicted are season onset, peak (circles), and offset for 4 
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methods: (1) the 10% threshold method (yellow bar and circle), (2) the 3% threshold method 
(green bar and circle), (3) the 10FB method (blue bar and circle), and (4) the RS10 method 
(black bar and circle). All data are limited to National Respiratory and Enteric Virus 
Surveillance System (NREVSS) laboratories that consistently reported data, defined here as 
those that reported data for an average of ≥10 RSV tests per week annually for at least 30 
weeks of NREVSS-defined year. Surveillance started at week 27 for all years except 2009–
2010, during which it started at week 26. Calendar years ended at week 52 for all years 
except 2014, which ended at week 53.
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Table 1
Features, Strengths, and Limitations of 4 Methods for Determining Respiratory Syncytial 
Virus (RSV) Seasons, Using Testing Data From the National Respiratory and Enteric 
Virus Surveillance System (NREVSS)
Feature Retrospective Slope 10 10-Fold Baseline 3% Threshold 10% Threshold (Traditional)
Test type PCR PCR PCR Antigen based
Data Weekly no. of RSV detections Weekly no. of RSV 
detections
Weekly percentage of tests 
positive for RSV
Weekly percentage of tests positive 
for RSV
Data function Centered 5-week moving 
average normalized to a peak 
of 1000 detections
4-week moving 
average, using 
detections in 2 
preceding weeks, 
current week, and 
following week
None None
Onset Second of 2 consecutive 
weeks when simple increase 
in normalized 5-week moving 
average of RSV detections 
between subsequent weeks 
(ie, slope) was >10, provided 
that slope remained at least 10 
from that week forwardThe 
normalized 5-week moving 
average of RSV detections at 
onset equals α
First of 2 consecutive 
weeks when 4-week 
moving average of 
RSV detections is >10 
times the 4-week 
moving average at 
week 29
First of 2 consecutive 
weeks when percentage of 
tests positive for RSV is 
>3%
First of 2 consecutive weeks when 
percentage of tests positive for 
RSV is >10%
Offset Last week that normalized 5-
week moving average of RSV 
detections exceeds α
Last week that 4-week 
moving average of 
RSV detections is >10 
times the 4-week 
moving average at 
week 29
Last week that percentage 
of tests positive for RSV is 
>3%
Last week that percentage of tests 
positive for RSV is >10%
Strengths Testing practices have less 
influence on season because 
testing denominator is 
excludedPercentage captured 
in season is consistent 
between yearsOnset 
consistently reflects a notable 
infection point in RSV 
detectionsRegion-specific 
approach because measure is 
relative to normalized regional 
peakData are normalized at 
peak of season, when most 
laboratories are reporting to 
NREVSS
Applied in near real 
timeTesting practices 
have less influence on 
season because testing 
denominator is 
excludedRegion-
specific approach 
because measure is 
relative to regional 
baseline
Applied in near real time 
Simple to useA possible 
approach in locales where 
RSV testing or reporting 
are not performed 
throughout the year; this is 
because (1) number of 
weekly tests performed are 
incorporated and (2) 
weekly percentage of tests 
positive for RSV is not 
relative to that for other 
weeks
Applied in near real time Simple to 
use
Limitations Not applied in real timeYear-
round RSV testing and 
reporting is required 
(including summer months) 
because (1) testing 
denominator has been 
excluded and (2) data are 
presented relative to other 
weeks
Year-round RSV 
testing and reporting is 
required (including 
summer months) 
because (1) testing 
denominator has been 
excluded and (2) data 
are presented relative to 
other weeksPercentage 
of detections captured 
within season is less 
consistent between 
years and regions than 
for RS 10Data are 
relative to a time of 
year when RSV 
detections are low and 
fewer laboratories are 
reporting
Use of denominator means 
that testing practices can 
influence season; the 
following should be 
considered: (1) changing 
practices over time, (2) 
different practices between 
regions, and (3) intention 
of test (antigen-detection 
tests are more typically 
RSV specific, but antigen 
panels are 
available)Percentage of 
detections captured within 
season is less consistent 
between years and regions 
than for RS 10A single-
value threshold might not 
be as precise for all 
Use of denominator means that 
testing practices can influence 
season. The following should be 
considered: (1) changing practices 
over time, (2) different practices 
between regions, and (3) intention 
of test (antigen-detection tests are 
more typically RSV-specific, but 
antigen panels are 
available)Percentage of detections 
captured within season is 
inconsistent between years and 
regionsA single-value threshold 
might not be as precise for all 
seasons and regions, especially as 
testing practices vary
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Feature Retrospective Slope 10 10-Fold Baseline 3% Threshold 10% Threshold (Traditional)
seasons and regions, 
especially as testing 
practices vary
Abbreviation: PCR, polymerase chain reaction.
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